Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Classificação em ações #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Preço da ação
$4.74
Última sincronização: 2026-08-31
Valor de mercado
$372.19M
Variação (1 dia)
-2.47%
Variação (1 ano)
-1.04%
País
US
Negociar Lexeo Therapeutics, Inc. Common Stock (LXEO)

Categoria

Histórico de preços das ações de Lexeo Therapeutics, Inc. Common Stock (LXEO)
Preço de fecho mais alto: $4.91 em 2026-08-01

Preço de fecho mais baixo: $11.06 em 2023-11-01
Histórico de preços das ações da Lexeo Therapeutics, Inc. Common Stock de 2023 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$745.74 4.52%
CH